Ariad Pharmaceuticals obtained accelerated FDA approval for Iclusig, or ponatinib, to treat patients with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. The drug, which was cleared three months ahead of schedule, inhibits certain proteins that promote cancer cell development. Iclusig will be sold with a boxed warning on its label about the risk of blood clots and liver poisoning.

Related Summaries